Portfolio

Adlore is a medical device company designing the next generation device for the treatment of lower extremity diffucult to heal wounds, i.e. diabetic/neuropathic foot ulcers, venous stasis leg wounds, arterial and ischemic ulcers.

Advertent Biotherapeutics is a biotech company targeting
disorders affecting the musculoskeletal system. It’s therapies
target the TGF-Beta superfamily growth factors that guide the
development and differentiation of all tissues in the human body.

Asalyxa Bio is focused on the development of an immune cell targeting platform to create first-in-class particle drug products for diseases with continuing high unmet medical needs.

Asalyxa Bio is focused on the development of an immune cell targeting platform to create first-in-class particle drug products for diseases with continuing high unmet medical needs.

CareLens is developing a surgical medical practice observation
intelligence system. The CareLens system, is based in AI powered
camera systems combined with customer specific AI models to
identify and report best practice clinical and surgical workflows to
maximize surgical efficiency and patient safety.

Coronation Bio is a biotech company commercializing two novel and distinct assets from University of Pennsylvania (UPenn) for weight loss in obese patients. Each of these assets have potential to be agents for weight loss to treat obesity without the often- severe side effects associated with GLP-1 weight loss drugs.

Coordinista provides an all-in-one SAAS care coordination solution for caseload management in decentralized healthcare delivery.

Tech-enabled healthcare services business that combines state of the art clinical microbiology processes and equipment with specialized sampling techniques to reduce healthcare-associated infections through subscription-bsed sampling, testing, and germ

Epsilon Imaging is a healthcare IT company transforming cardiac diagnostic workflow with a vendor neutral suite of software applications designed for echocardiography.

Espervita is developing metabolic reprogramming therapies for common forms of cancer, starting with Hepatocellular Carcinomoa as its first indications. The company is using a noval inhibitor for ATP-citrate Lyase.

EVOQ is developing therapeutic High-Density Lipoprotein (HHDL) nanodiscs which are capable of inducing immunological tolerization in patients as a means of treating autoimmune disorders and cancer.

Fifth Eye is developing software to warn medical professionals that certain patients who seem to be doing well after an operation are actually, based on almost imperceptible changes in their vital signs, at risk for serious deterioration in their conditions.

FlightPath is commercialization Hygromycin A and its derivatives,
an antibiotic that is highly selective against Borrelia burgdorferi,
the pathogen that causes Lyme. It is also set to treat infections
caused by related bacteria, collectively known as Spirochete
bacteria including syphilis, periodontal disease, and rare tropical
diseases such as treponema. FlightPath also has IP that is being
used to actively pursue other small molecule antibiotics
(Fabimycin and Lolamicin) targeting several pathogen-driven
diseases

GreenMark is a minimally invasive healthcare company, developing technologies that involve biopolymer nanoparticles produced from natural starch as a raw material.  Given that starch is degraded by natural enzymes in our body, starch nanoparticles are an ideal carrier for dental and medical applications.

Happe Spine is a medical device company focused on developing next generation orthopedic implants with a focus on modifying PEEK technology as fully porous and bioactive, which promotes bone ongrowth and bone ingrowth.

Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases. Iaso’s initial product offering is a disruptive new virus-like particle, mutant Qβ, that shows superiority in generating antibodies of interest.

INHERET is a digital health company empowering individuals to identify, understand, and manage their risks of hereditary conditions. It will identify individual risk to help personalize screening and therapy programs.

Intervention Insights (acquired by NeoGenomics) is a medical information services company that combines cutting edge bioinformatics tools with disease insight to specify molecularly targeted drugs to help community oncologists develop informed treatment plans for their patients.

M3D is focused on offering devices and services that leverage 3D CZT to the human medical market for real-time radiation imaging.

Magnesium Development Company is a medical device development company delivering a resorbable metal alloy technology for use in surgical screws/plates for application in sports medicine and foot & ankle orthopedics.

MediCool is developing cool cardioversion to painless treat and terminate dangerous cardiac arrhythmias and other disorders.

Native Traits is an agbio company formed to promote the development of its NT RECOVERYTM technology, a propritary technology that enables the company to use ancestral strains of corn, and other grain, as a natural source of genes to improve commercial varieties.

Ocuphire is a biopharmaceuticals company focused on developing and commercializing small molecule drugs for unmet medical needs in the ocular disease space. Ocuphire’s lead drug candidate, Nyxol eye drops, is aimed to treat patients with night vision disturbances (NVD), Glaucoma and Presbyopia (impaired near-term vision).

ONL Therapeutics is a biopharmaceutical company dedicated to the discovery and early clinical development of drugs to treat retinal disorders.

Parallel Robotics has developed the “MediBot” robotic system,
with the vision to make minimumly invasive surgery (MIS) using
robotics accessable and scalable worldwide.

PatentSee has developed a contactless imaging device for rapid
vascular access (VA) monitoring of hemodialysis patients.

Peptinovo is developing a novel peptide-based delivery platform, Peptide-Amphiphile Lipid Micelle (PALM™), using cancer’s growth pathway to safely carry stronger doses of proven drugs directly into tumors while keeping them away from healthy tissue.

Reprise Pharmaceuticals is a spin off from Remedy Pharmaceuticals which is developing a drug therapy using the combination of a sulfonylurea drug with another repurposed drug in the treatment of multiple sclerosis (MS), one that could provide an improved treatment option for a subset of multiple sclerosis patients.

SBE Medical is a medical device company with its primary product the Tibbe External Female Urine Collection Device (EUD), a non-invasive external catheter designed to reduce Catheter-Associated Urinary Tract Infections (CAUTIs), an alternative to indwelling Foley catheters

SeaStar (fka CytoPherx) Medical is a device company developing therapies to reduce mortality amoung patients with acute kidney failure due to a combination of acute kidney injury, sepsis, and/or multi-organ failure.

Shoulder Innovations is a medical device development company that has developed inset glenoid fixation technology, creating the most robust and stable glenoid platform in the industry, The company’s Total Shoulder Replacement System addresses the most significant issue in shoulder arthroplasty: unreliable fixation of the glenoid implant.

Vestaron Corporation has developed and commercialized a new generation of insecticides derived from peptides produced by spiders.

ZuChem is a producer of unique sugars for human consumption. Its primary product is xylitol, based upon carbohydrate chemistry using a scalable manufacturing process.